rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2007-3-5-115-120rpcardio-569Research ArticleEVIDANCE BASED MEDICINEДОКАЗАТЕЛЬНАЯ МЕДИЦИНАWHETHER THE STUDY ON EFFICACY OF ROSUVASTATIN IN ELDERLY PATIENTS WITH HEART FAILURE AND SYSTOLIC DYSFUNCTION OF LEFT VENTRICLE HAD BEEN COMPLETED WITH “CROWNING”?ЗАВЕРШИЛОСЬ ЛИ «КОРОНАЦИЕЙ» ИССЛЕДОВАНИЕ ПО ОЦЕНКЕ ЭФФЕКТИВНОСТИ ПРИМЕНЕНИЯ РОЗУВАСТАТИНА У БОЛЬНЫХ ПОЖИЛОГО ВОЗРАСТА С СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ И НАРУШЕНИЕМ СИСТОЛИЧЕСКОЙ ФУНКЦИИ ЛЕВОГО ЖЕЛУДОЧКА?ГиляревскийС. Р.GilyarevskyS. R.20070301201635115120Copyright © Gilyarevsky S.R., 20152015Гиляревский С.Р.Gilyarevsky S.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/569

Whether the study on efficacy of rosuvastatin in elderly patients with heart failure and systolic dysfunction of left ventricle had been completed with “crowning”?

Источник: Kjekshus J, Apetrei E, Barrios V, et al.; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61.

Одним из главных событий доказательной кардиологии стало опубликование результатов исследования CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). Полученные данные могут существенно повлиять на тактику применения статинов у больных с хронической сердечной недостаточностью (ХСН), развившейся на фоне ишемической болезни сердца (ИБС).

ReferencesKrum H., McMurray J.J. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol 2002;39:1567-73.Krum H., McMurray J.J. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol 2002;39:1567-73.Böhm M., Hjalmarson A., Kjekshus J., et al. Heart failure and statins – why do we need a clinical trial? Z Kardiol 2005;94(4):223-30.Böhm M., Hjalmarson A., Kjekshus J., et al. Heart failure and statins – why do we need a clinical trial? Z Kardiol 2005;94(4):223-30.Kjekshus J., Dunselman P., Blideskog M., et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 2005;7(6):1059-69.Kjekshus J., Dunselman P., Blideskog M., et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 2005;7(6):1059-69.Cleland J.G., Loh H., Windram J., et al. Threats, opportunities, and statins in the modern management of heart failure. Eur Heart J 2006;27(6):641-3.Cleland J.G., Loh H., Windram J., et al. Threats, opportunities, and statins in the modern management of heart failure. Eur Heart J 2006;27(6):641-3.Horwich T.B., Hamilton M.A., Maclellan W.R., Fonarow G.C. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002;8:216-24.Horwich T.B., Hamilton M.A., Maclellan W.R., Fonarow G.C. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002;8:216-24.Rauchhaus M., Clark A.L, Doehner W., et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003;42:1933-40.Rauchhaus M., Clark A.L, Doehner W., et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003;42:1933-40.Rauchhaus M., Coats A.J., Anker S.D. The endotoxin-lipoprotein hypothesis. Lancet 2000;356:930-3.Rauchhaus M., Coats A.J., Anker S.D. The endotoxin-lipoprotein hypothesis. Lancet 2000;356:930-3.Marcoff L., Thompson P.D. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007;49:2231- 7.Marcoff L., Thompson P.D. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007;49:2231- 7.Moosmann B., Behl C. Selenoprotein synthesis and side-effects of statins. Lancet 2004;363:892-4.Moosmann B., Behl C. Selenoprotein synthesis and side-effects of statins. Lancet 2004;363:892-4.Uretsky B.F., Thygesen K., Armstrong P.W., et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 2000;102:611-6.Uretsky B.F., Thygesen K., Armstrong P.W., et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 2000;102:611-6.Orn S., Cleland J.G., Romo M, et al. Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. Am J Med 2005;118:752-8.Orn S., Cleland J.G., Romo M, et al. Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. Am J Med 2005;118:752-8.Krum H,, Latini R., Maggioni A.P., et al. Statins and symptomatic chro￾nic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol 2007;119:48-53.Krum H,, Latini R., Maggioni A.P., et al. Statins and symptomatic chro￾nic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol 2007;119:48-53.Go A.S., Lee W.Y., Yang J., et al. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 2006;296:2105-11.Go A.S., Lee W.Y., Yang J., et al. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 2006;296:2105-11.van der Harst P., Voors A.A., van Gilst W.H., et al. Statins in the treatment of chronic heart failure: a systematic review. PLoS Med 2006;3(8):e333.van der Harst P., Voors A.A., van Gilst W.H., et al. Statins in the treatment of chronic heart failure: a systematic review. PLoS Med 2006;3(8):e333.Martin J.H., Krum H. Statins and clinical outcomes in heart failure. Clin Sci (Lond) 2007;113:119-27.Martin J.H., Krum H. Statins and clinical outcomes in heart failure. Clin Sci (Lond) 2007;113:119-27.Krum H., Ashton E., Reid C., et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and ne￾urohormonal parameters in patients with chronic systolic heart failure. J Card Fail 2007;13:1-7.Krum H., Ashton E., Reid C., et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and ne￾urohormonal parameters in patients with chronic systolic heart failure. J Card Fail 2007;13:1-7.Collins R., Armitage J., Parish S., et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-67.Collins R., Armitage J., Parish S., et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-67.Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360:1623-30.Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360:1623-30.Hjalmarson A., Goldstein S., Fagerberg B., et al. Effects of controlledrelease metoprolol on total mortality, hospitalizations, and wellbeing in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000;283:1295-302.Hjalmarson A., Goldstein S., Fagerberg B., et al. Effects of controlledrelease metoprolol on total mortality, hospitalizations, and wellbeing in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000;283:1295-302.Pedersen T.R., Kjekshus J., Berg K., et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.Pedersen T.R., Kjekshus J., Berg K., et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.Tavazzi L., Tognoni G., Franzosi M.G., et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 2004;6:635-41.Tavazzi L., Tognoni G., Franzosi M.G., et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 2004;6:635-41.

The authors declare that there are no conflicts of interest present.